You are here:

Forthcoming Submissions:

PACE medicines

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due
afamelanotide (Scenesse) Clinuvel (UK) Ltd Full submission 1/05/2017 Q3 2017 Q3 2017
cabozantinib (Cabometyx) Ipsen Ltd Full submission 6/03/2017 2/05/2017 12/06/2017
carfilzomib (Kyprolis) Amgen Ltd Full submission 3/04/2017 Q3 2017 Q3 2017
etelcalcetide (Parsabiv) Amgen Ltd Full submission 5/06/2017 Q3 2017 Q3 2017
idebenone (Raxone) Santhera Pharmaceuticals Full submission 6/02/2017 4/04/2017 8/05/2017
nivolumab (Opdivo) for Hodgkin lymphoma Bristol-Myers Squibb Pharmaceuticals Ltd Full submission 3/04/2017 6/06/2017 10/07/2017
nivolumab (Opdivo) for RCC Bristol-Myers Squibb Pharmaceuticals Ltd Resubmission 6/03/2017 2/05/2017 12/06/2017
nivolumab (Opdivo) SCCHN Bristol-Myers Squibb Pharmaceuticals Ltd Full submission 5/06/2017 Q3 2017 Q3 2017
obeticholic acid (Ocaliva) Intercept Pharmaceuticals Full submission 6/03/2017 2/05/2017 12/06/2017
pembrolizumab (Keytruda) - 1st Line NSCLC MSD Full submission 3/04/2017 6/06/2017 10/07/2017
pertuzumab (Perjeta) Roche Resubmission 6/02/2017 2/05/2017 12/06/2017
selexipag (Uptravi) Actelion Pharmaceuticals UK Ltd Full submission 6/03/2017 6/06/2017 10/07/2017
stiripentol (Diacomit) BIOCODEX Resubmission 1/05/2017 Q3 2017 Q3 2017
venetoclax (Venclyxto) AbbVie Ltd Full submission 1/05/2017 Q3 2017 Q3 2017

Non-PACE medicines

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due
ustekinumab (Stelara) Janssen-Cilag Ltd Full submission 1/05/2017 6/06/2017 10/07/2017
5-aminolevulinic acid hydrochloride (Ameluz) Biofrontera Bioscience GmbH Full submission 5/06/2017 4/07/2017 7/08/2017
adalimumab (Humira) AbbVie Ltd Abbreviated Submission N/A 2/05/2017 12/06/2017
aprepitant (Emend) MSD Full submission 3/04/2017 2/05/2017 12/06/2017
aprepitant (Emend) MSD Abbreviated Submission N/A 6/06/2017 10/07/2017
baricitinib (Olumiant) Eli Lilly and Company Ltd Full submission 3/07/2017 1/08/2017 11/09/2017
belimumab (Benlysta) GlaxoSmithKline UK Ltd Resubmission 6/03/2017 4/04/2017 8/05/2017
budesonide-formoterol (Symbicort SMART) AstraZeneca UK Ltd Abbreviated Submission N/A 2/05/2017 12/06/2017
buprenorphine oral lyophilisate (Espranor) Martindale Pharma Abbreviated Submission N/A 2/05/2017 12/06/2017
ciprofloxacin/dexamethasone (Cilodex) Novartis Pharmaceuticals UK Ltd Abbreviated Submission N/A 6/06/2017 10/07/2017
deferasirox (Exjade) Novartis Pharmaceuticals UK Ltd Abbreviated Submission N/A 2/05/2017 12/06/2017
desmopressin oral lyophilisate (Noqdirna) Ferring Pharmaceuticals Ltd Resubmission 5/06/2017 4/07/2017 7/08/2017
dolutegravir (Tivicay) ViiV Healthcare/GSK Abbreviated Submission N/A 6/06/2017 10/07/2017
glycopyrronium bromide (Sialanar) Proveca Limited Abbreviated Submission N/A 6/06/2017 10/07/2017
micronised progesterone (Utrogestan Vaginal) Besins Healthcare (UK) Ltd Full submission 6/03/2017 4/04/2017 8/05/2017
roflumilast (Daxas) AstraZeneca UK Ltd Resubmission TBC TBC TBC
saxagliptin - dapagliflozin (Qtern) AstraZeneca UK Ltd Abbreviated Submission N/A 6/06/2017 10/07/2017

Medicines with advice withheld pending product availability

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due
dinutuximab (Unituxin) United Therapeutics Full submission 31/10/2015 6/01/2016 TBC
empaglifozin linagliptin fixed-dose combination (Glyxambi) Boehringer Ingelheim Ltd Abbreviated Submission N/A 4/04/2017 TBC
nepafenac (Nevanac) Alcon Laboratories UK Ltd Abbreviated Submission N/A 7/03/2017 TBC
oritavancin (Orbactiv) The Medicines Company Full submission 2/11/2015 1/12/2015 TBC
reslizumab (Cinqaero) Teva UK Limited Full submission 6/03/2017 4/04/2017 TBC

Back